Somatic mutations in nucleophosmin (NPM1) occur in approximately 35% of adult acute myeloid leukemia (AML). To assess the frequency of NPM1 mutations in pediatric AML, we sequenced NPM1 in the diagnostic blasts from 93 pediatric AML patients. Six cases harbored NPM1 mutations, with each case lacking common cytogenetic abnormalities. To explore the phenotype of the AMLs with NPM1 mutations, gene expression profiles were obtained using Affymetrix U133A microarrays. NPM1 mutations were associated with increased expression of multiple homeobox genes including HOXA9, A10, B2, B6 and MEIS1. As dysregulated homeobox gene expression is also a feature of MLL-rearranged leukemia, the gene expression signatures of NPM1-mutated and MLL-rearranged leukemias were compared. Significant differences were identified between these leukemia subtypes including the expression of different HOX genes, with NPM1-mutated AML showing higher levels of expression of HOXB2, B3, B6 and D4. These results confirm recent reports of perturbed HOX expression in NPM1-mutated adult AML, and provide the first evidence that the NPM1-mutated signature is distinct from MLL-rearranged AML. These findings suggest that mutated NPM1 leads to dysregulated HOX expression via a different mechanism than MLL rearrangement.
Introduction
Pediatric de novo acute myeloid leukemia (AML) is a heterogeneous disease that consists of distinct subtypes characterized by specific genetic lesions. These include the t(15:17), t(8;21) and inv (16) chromosomal translocations, and rearrangement of MLL at 11q23. These chromosomal abnormalities form the basis for a diagnostic classification that is used to risk stratify patients so that they can be optimally treated. 1 Mutations have been identified in AML blasts in the RUNX1 (AML1), FLT3, CEBPA, PU.1 and EVI1 genes, some of which influence prognosis. [2] [3] [4] [5] [6] [7] [8] Recent studies in adult AML have identified a high frequency of mutations of the nucleophosmin (NPM1) gene in cases that lack recurring cytogenetic abnormalities. [9] [10] [11] [12] [13] [14] Importantly, the presence of NPM1 mutations has been associated with a favorable outcome.
Nucleophosmin is a widely expressed protein predominantly located in the nucleolus that continuously shuttles between nucleus and cytoplasm. 15, 16 Nucleophosmin is involved in multiple cellular functions, including ribosomal biogenesis, centrosomal duplication and maintenance of genomic integrity.
NPM is also a nucleolar binding partner of p14 Arf 17 and through this interaction regulates the stress-induced activity of p53.
18
NPM1 is disrupted by several translocations in hematopoietic malignancies that fuse the N terminus of NPM with partner genes including anaplastic lymphoma kinase in lymphoma (NPM-ALK), 19 retinoic acid receptor-a in premyelocytic leukemia (NPM-RARA), 20 and myeloid leukemia factor 1 in myelodysplasia (NPM-MLF1). 21 These translocations appear to dysregulate the activity of the fusion partner, 22 and translocate NPM to the cytoplasm. 16 In addition to these chromosomal rearrangements, recent efforts by Falini et al. 11, 23, 24 demonstrated the presence of mutations that disrupted the C terminus of NPM and result in aberrant cytoplasmic localization of NPM in approximately one-third of cases of adult AML. This finding has been validated by others and, collectively, these studies have found that NPM1 mutations are associated with older age, normal karyotype, lack of CD34 expression, monocytic morphology and FLT3 internal tandem duplication mutations. [9] [10] [11] [12] [13] [14] NPM1 mutations have also been associated with a favorable response to induction chemotherapy and superior overall and event-free survival, at least in patients lacking FLT3 mutations. [10] [11] [12] [13] Data in the pediatric setting are more limited, with existing reports suggesting NPM1-mutations are less frequent than in adult AML, and occur predominantly in older patients. 25 The mechanisms by which NPM1 mutations contribute to leukemogenesis are unclear. 26 NPM regulates the p14 ARF -MDM2/ p53 pathway, and the identified NPM1 mutations result in translocation of NPM and p14 ARF to the cytoplasm, preventing the interaction of ARF with Mdm2, the negative regulator of p53. 27 However, perturbation of ARF function appears insufficient to explain the oncogenic effects of mutant NPM1. 27 Gene expression profiling is a powerful tool to investigate the pathogenesis of acute leukemia. [28] [29] [30] Existing data from NPM1-mutated adult AML have identified dysregulated expression of homeobox (HOX) and TALE genes known to be involved in hematopoietic development. 13, 31 This pattern is reminiscent of MLL-rearranged leukemias; 28, 32 however, the signatures of NPM1-mutant and MLL-rearranged leukemias have not been directly compared.
To investigate the importance of NPM1 mutations in pediatric AML, we have investigated a cohort of 93 patients encompassing all common diagnostic and cytogenetic subgroups. In addition to NPM1 genotyping, gene expression profiling using Affymetrix U133A microarrays was used to define an expression signature of NPM1-mutated leukemia.
Materials and Methods

Samples
Ninety-three patients treated at St Jude Children's Research Hospital from 1981 to 2005 were studied. Informed consent for the use of leukemic cells for research was obtained from patients, parents or guardians in accordance with the Declaration of Helsinki, and study approval was obtained from the SJCRH Institutional Review Board. The majority of patients were treated on protocols AML80, AML83, AML87, AML91, AML97 and AML02. 33 The t(15;17) cases were treated on POG9710 or according to best clinical management.
AML samples were classified according to revised FAB criteria. 34 Purification of mononuclear cells from diagnostic marrow (n ¼ 89) or peripheral blood (n ¼ 4) was performed as described previously. 28 Samples were analyzed by conventional cytogenetics and reverse-transcription (RT)-PCR for the presence of PML-RARA, RUNX1-RUNX1T1 (AML1-ETO) and CBFB-SMMHC transcripts. MLL rearrangement was identified by cytogenetics, 11q23 fluorescence in situ hybridization (FISH) and/or RT-PCR for t(9;11)(MLL-AF9, n ¼ 4); t(11;19) (one MLL-ENL positive case and two MLL-ELL positive cases confirmed by RT-PCR, and one t(11;19) case confirmed by FISH); one MLL-AF10 positive case (confirmed by RT-PCR); and one case each with t(1;11) and t(6;11) (confirmed by FISH).
NPM1 genotyping
Genomic DNA was extracted from cryopreserved mononuclear cell preparations of diagnostic marrow or blood samples using the Qiagen DNA blood mini kit (Qiagen, Valencia, CA, USA). Exon 12 of NPM1 was amplified using Accuprime Pfx DNA polymerase (Invitrogen, Carlsbad, CA, USA) and the primers NPM1-F 5 0 -TTAACTCTCTGGTGGTAGAATGAA and NPM1-R 5 0 -CAAG ACTATTTGCCATTCCTAAC.
11 PCR products were purified and sequenced directly using the NPM1_1112R primer 5 0 -CCTGGA CAACATTTATCAAACACGGTA and Big Dye Terminator (v.3.1) chemistry on 3730xl DNA analyzers (Applied Biosystems, Foster City, CA, USA). NPM1 mutations were confirmed by cloning PCR products into the pCR 2.1-TOPO vector (Invitrogen) and performing bidirectional sequencing of multiple clones.
FLT3 mutation detection
Genomic DNA of FLT3 exons 14, 15 and 20 corresponding to the juxtamembrane and tyrosine kinase domains were amplified using Accuprime Pfx using primers 5 0 -CATTGTCGTT TTAACCCTGCT and 5 0 -CCTTGAAACATGGCAAACAGT (exons 14/15) and 5 0 -TCCATCACCGGTACCTCCTA and 5 0 -CCATG ATAACGACACAACACAA (exon 20). PCR products were purified and sequenced as described above.
Gene expression profiling
RNA isolation from diagnostic bone marrow or peripheral blood mononuclear cell suspensions, cDNA and cRNA synthesis, labeling, fragmentation, hybridization and scanning of Affymetrix HG-U133A oligonucleotide microarrays were performed as described previously. 28 Gene expression signals were scaled to a target intensity of 500, and detection values were determined using the default settings of Affymetrix Microarray Suite 5.0. Quality control criteria for inclusion in the study were greater than 10% present calls, and glyceraldehyde-3-phosphate dehydrogenase and b-actin 3 0 to 5 0 signal intensity ratios of p3. The mean present call rate was 3875.7% (range, 20.2-46.8%), and the mean glyceraldehyde-3-phosphate dehydrogenase (GAPDH)/actin ratio was 1.04770.335 (range 0.750-2.89) (Supplementary Table 1) .
Analysis of differential gene expression was performed by t-test using the R statistical package (http://cran.r-project.org/), with estimation of false discovery rate (FDR, q-value) and proportion of differentially expressed genes (1Àp 0 ) by the method of Storey. 35, 36 Gene expression data were visualized using GeneMaths XT 1.61 (Applied Maths, Austin, TX, USA). To define the gene expression signature of NPM1-mutant AML, gene expression profiles of NPM1-mutant cases were compared with profiles of NPM1-wild-type cases lacking common cytogenetic abnormalities (RUNX1-RUNX1T1, CBFB-SMMHC, PML-RARA, MLL rearranged) or M7 phenotype, and by comparing NPM1-mutant cases with the entire NPM1-wild-type cohort. To compare the signatures of NPM1-mutant and MLLrearranged AML, the NPM1-mutant signature was defined by comparing the gene expression profile of NPM1-mutant cases with NPM1-wild-type, non-MLL rearranged AML, and the signature of MLL-rearranged AML was defined by comparing MLL cases with non-MLL-rearranged, NPM1-wild-type AML.
Quantitative real-time PCR
Expression of HOXB2 and HOXB6 was measured in NPM1-mutated (n ¼ 4) and MLL-rearranged (n ¼ 12) samples using Taqman assays-on-demand Hs00609873_g1 (HOXB2) and Hs00255831_s1 (HOXB6) (Applied Biosystems). RNA was extracted using TRIzol (Invitrogen), and reverse transcribed using random hexamer primers and Multiscribe Reverse Transcriptase (Applied Biosystems). Taqman assays were performed using a 7500 real-time PCR system and 7500 System Software (Applied Biosystems), using the 7500 universal cycling conditions: 501C for 2 min, followed by 951C for 10 min, then 40 cycles of 951C for 1 min and 601C for 1 min. Standard curves for GAPDH and HOXB2/B6 gene expression were generated from 10-fold serial dilutions of the K562 (HOXB2) and CMK (HOXB6) cell lines (obtained from the Deutsche Sammlung von Mikroorganismen und Zellkulturen, DSMZ, Braunschweig, Germany). These normalized ratios were compared to each other for differences in overall levels of PAX5 expression. Assays were performed in duplicate and mean values reported.
Statistical analyses
Pairwise comparisons of patient clinical and laboratory variables were performed using the Mann-Whitney test (continuous variables) and the Fisher's exact test (categorical variables). The Kaplan-Meier method was used to estimate the probabilities of event-free and overall survival, 37 and standard errors were determined using the method of Peto and Pike. 38 Event-free survival was defined as the time elapsed from study enrollment to first event (remission induction failure, relapse, death or second malignancy). When patients did not achieve remission, the eventfree survival time was set to zero. Patients who had not yet experienced any of these events were censored at last follow-up. Overall survival was defined as the time elapsed from study enrollment to death, with those still living at last follow-up censored. The exact log-rank test was used to compare the eventfree and overall survival of those AML cases with NPM1 mutations to that of the NPM1-wild-type cases. These analyses of clinical features and outcome were not adjusted for multiple testing.
Results
Clinical and laboratory features of NPM1-mutated pediatric AML
Sequence analysis of exon 12 of NPM1 identified the presence of mutations in 6 of the 93 pediatric AML cases analyzed (6.4%) (Tables 1 and 2 ). The mutations were tetranucleotide insertions at nucleotide position 960 (Genbank accession NM_002520) and corresponding to the previously described mutation types A, B and D of Falini et al. 11 Each mutation led to the replacement of the seven C-terminal amino acids of NPM1 with 11 different residues that contained a nuclear export sequence. In each case, the mutations were heterozygous, and a wild-type NPM1 allele was retained. The clinical and laboratory characteristics of the patients stratified by NPM1 mutation status are shown in Table 1 . The median age at diagnosis was significantly higher in patients with NPM1 mutations (14.6 vs 9.7 years, P ¼ 0.045). A similar age-dependent distribution of NPM1 mutations has previously been described in both adult and pediatric AML cohorts. 13, 25 NPM1 mutations were only detected in cases of AML with normal karyotype (n ¼ 3) or nonrecurring cytogenetic anomalies (inv(5), add (17) and trisomy 4). There was no significant difference in presentation peripheral blood leukocyte counts between NPM1-mutated and wild-type cases. Three of the six NPM1-mutated cases displayed morphologic evidence of monocytic differentiation. All cases showed low or absent expression of CD34, and, where measured (n ¼ 4), CD117 and CD133. One of the six NPM1-mutated cases had an FLT3 mutation ( Table 2) .
Survival analyses did not detect associations between NPM1 mutations and outcome, although this may be due to limited statistical power. The 6-year event-free survival was 55.6726.2 and 37.677.2% for those with and without the mutation, respectively (P ¼ 0.186, Table 1 ). Similarly, the 6-year OS was 41.7722.5 and 49.777.2% for those with and without the mutation, respectively (P ¼ 0.468).
Gene expression signature of NPM1-mutated AML Unsupervised clustering of AML cases lacking recurring cytogenetic abnormalities (n ¼ 41) was performed using the squared Pearson similarity coefficient and the unweighted pairgroup method using arithmetic averages (UPGMA) clustering algorithm in GeneMaths XT. This demonstrated partial clustering of NPM1-mutant cases, with four NPM1-mutated cases clustering in two groups (Supplementary Figure 1) . This suggests that NPM1 mutations influence, but are not the sole determinant of, the overall gene expression profiles of NPM1-mutated AML cases.
The gene expression signature for NPM1-mutated AML was defined by comparing the six NPM1-mutant cases with all NPM1-wild-type cases (NPM1-mutated signature 1), and also by Figure 1 and Supplementary  Figure 3) . A total of 196 probe sets were shared by both NPM1-mutated signatures (Supplementary Table 4 ). The majority of the remaining 246 probe sets in the NPM1-mutated signature 1 also showed trends to differential expression in the NPM1-mutant vs normal/miscellaneous AML (signature 2) comparison, but did not meet the specified FDR criterion of 0.2 (125 probe sets with Po0.01 and 0.2oqo0.34; and 105 probe sets with 0.01oPo0.1 and 0.34oqo0.64). Both NPM1-mutated signatures were characterized by dysregulated homeobox (HOX) gene expression, including increased expression of HOXA2, A5, A6, A7, A10, B2, B3 and B6, and reduced expression of HOXC4. Increased expression of HOXD4 was also observed in NPM1-mutated signature 1. Expression of all HOX U133A probe sets is shown in Figure 2 . NPM1-mutant cases also exhibited upregulation of the TALE homeodomain proteins MEIS1 (myeloid ecotropic viral integration site 1 homolog) and PBX3, and reduced expression of CD7, CD34, GAS6 (growth arrest-specific 6), the TGFb regulatory gene LTBP4, and the putative tumor suppressor NBL1.
The increased expression of members of the HOX gene family was reminiscent of acute leukemia with rearrangements of the MLL gene. 32 To compare formally the signatures of NPM1-mutated and MLL-rearranged pediatric AML, we defined an expression signature for MLL-rearranged leukemia by comparing the profiles of MLL rearranged cases (n ¼ 13) to all MLL-wildtype cases (MLL signature 1; 744 differentially expressed probe sets at FDR ¼ 5%, Supplementary Table 5) , and to MLL-wildtype, NPM1-wild-type cases (MLL signature 2; 838 probe sets at FDR ¼ 5%, Supplementary Table 6 ). Both signatures were characterized by increased expression of HOXA4, A5, A6, A7, A9, A10, B9 and MEIS1, and reduced expression of HOXB2 (Supplementary Tables 5 and 6 ). To compare the gene expression profiles of NPM1-mutated and MLL-rearranged AML, we defined a gene expression signature of NPM1-mutant AML excluding MLL-rearranged cases from the analysis (NPM1 signature 3; 566 probe sets at FDR threshold of 20%, Supplementary Table 7) , and examined overlap between this signature and MLL signature 2 described above.
Sixty-nine probe sets were common to both NPM1-mutated and MLL-rearranged leukemia signatures, including increased expression of HOXA4, A6, A7, A9 and B9, and the TALE genes MEIS1 and PBX3 (Supplementary Table 8 ). However, there were significant differences between the two signatures (Supplementary Table 9 and Figure 3 ). The homeobox B family genes HOXB2, B3, B5 and B6, as well as HOXD4 were overexpressed in NPM1-mutated AML but not MLL-rearranged leukemias. These differences in HOXB2 and HOXB6 expression were confirmed by quantitative RT-PCR in cases with available material (Figure 4) . Genes including SERPINF1, the megakaryocytic leukemia fusion partner MKL1, and members of the RAS superfamily RAB4A and RAC2 were overexpressed in MLLrearranged leukemia but not NPM1-mutant AML.
Of note, MLL-rearranged AML cases exhibited earlier age of diagnosis (median 4.00 vs 14.37 years, P ¼ 0.004, a trend to higher presentation peripheral blood leukocyte count 
2 B gat ctc tgc atg gca gtg gag gaa gtc tct tta aga aaa tag
A gat ctc tgt ctg gca gtg gag gaa gtc tct tta aga aaa tag
B gat ctc tgc atg gca gtg gag gaa gtc tct tta aga aaa tag
Abbreviations: FAB, French-American-British morphologic classification of AML; ITD, FLT3 internal tandem duplication; ND, not done; WT, wild type. Tetranucleotide insertions and predicted coding sequence changes are shown based on Genbank accession NM_002520. Insertions are underlined, and the resulting terminal amino acid sequence change shown in bold. Conserved residues of the putative consensus nuclear export signal motif in NPM mutant proteins (Lx(1-3)Lx(2-3)LxL) 39 are italicized.
Gene expression profiling of NPM1-mutated pediatric AML CG Mullighan et al Figure 1 Gene expression profiling of NPM1-mutated AML. Heat map displaying the top 30 upregulated and top 30 downregulated genes in NPM1-mutated AML compared to NPM1-wild-type cases lacking common cytogenetic abnormalities or M7 phenotype (NPM1-mutated signature 2), arranged by rank. Differentially expressed probe sets were identified by t-test at an FDR of 20%. Differentially expressed probe sets are listed in Supplementary Table 3 , and a heatmap of all differentially expressed probe sets is shown in Supplementary Figure 3. (P ¼ 0.136) and a strong association with myelomonocytic (FAB M5) morphology in comparison with NPM1-mutated AML (Supplementary Table 10 ).
Discussion
Our analysis confirmed the occurrence of NPM1 mutations in pediatric AML. As in prior studies, we found that NPM1 mutations were confined to those cases lacking a common cytogenetic abnormality or M7 phenotype. 11, 13, 25 Specifically, NPM1 mutations were identified in 6.4% of the analyzed pediatric cases and this frequency increased to 15% of those cases that lacked a common cytogenetic abnormality. Importantly, however, the frequency of NPM1 mutations was significantly lower in pediatric AML cases than in adult AML cases. This observation is in agreement with previously reported data in pediatric AML. 25 The NPM1 mutations detected in our cohort were identical to those previously described 11 and in each case led to the acquisition of a new nuclear export sequence at the protein's C-terminus. The NPM1 mutations were associated with older age at diagnosis. In addition, response to remission-induction therapy and survival appeared favorable for the NPM1-mutant cases, however, due to the small number of these cases, the differences were not statistically significant. In contrast to adult AML cohorts, 10, 12, 13 and consistent with previously reported pediatric AML data, 25 we observed a low frequency of FLT3 mutations in NPM1-mutated AML (1 of 6 cases).
An analysis of the gene expression profiles of NPM1-mutant AML provided important insights into the biology of this disease. Consistent with previous reports, 13, 31 NPM1-mutated AML displayed increased expression of numerous HOX genes, as well as the TALE homeodomain proteins MEIS1 and PBX3. A novel and important finding from this study was that the pattern of HOX dysregulation in NPM1-mutant cases was distinct from that observed in MLL-rearranged leukemias. There was upregulation of group B HOX genes in NPM1-mutated, but not MLLrearranged AML. Notably, HOXB2 and B6 exhibited high absolute U133A expression levels (mean 777.7 and 2363.3, respectively) and over 12-fold higher expression in NPM1-mutated AML in comparison to MLL rearranged cases (Supplementary Table 9 ). In contrast, HOXB3, HOXD4 and HOXB5 showed a less striking increased expression in NPM1-mutant cases (3.7-, 2.4-and 2.0-fold, respectively). These novel observations suggest that HOXB6 and B2 overexpression are biologically important markers of NPM1-mutated leukemia.
HOX genes encode proteins that bind DNA through a conserved homeodomain. HOX genes are arranged in four groups (A-D) on different chromosomes. 40 Orderly HOX gene expression is required both for normal embryogenesis and hematopoiesis, and the HOX genes have key roles in stem cell self-renewal and lineage commitment. 40, 41 Members of the HOX A and B paralog groups are particularly important for hematopoietic stem cell maintenance and expansion. Dysregulation of HOX gene expression is common in several types of leukemia, 42, 43 most notably in myeloid and lymphoid leukemias with MLL gene rearrangement, 28, 32, 44 and is important in leukemogenesis. Enforced overexpression of HOX genes in murine hematopoietic precursors induces AML. [45] [46] [47] The latency of HOX-induced leukemia is reduced when MEIS1, which is also overexpressed in NPM1-mutated leukemia, is also overexpressed. 48 Our finding of increased expression of HOXB2, B3, B5, B6 and HOXD5 in NPM1-mutated but not MLL-rearranged cases suggests that dysregulated expression of these genes may be important in the pathogenesis of AML with NPM1 mutations. Overexpression of HOXB6 in murine bone marrow immortalizes a myelomonocytic precursor and results in AML in vivo, the latency of which is reduced with MEIS1 coexpression. 49 Moreover, HOXB6 is selectively expressed in CD34 À cells, 42, 50 and it is interesting to note that cases of NPM1-mutated AML are commonly of myelomonocytic or monocytic morphology, and lack CD34 expression. Recent data suggesting that NPM1-mutated AML is derived from a common myeloid or earlier progenitor are compatible with these observations. 51 Overexpression of HOXB3 and HOXB4, which are also selectively upregulated in NPM1-mutant AML, also expands primitive hematopoietic precursors and promotes myeloproliferation. 45, 52, 53 Although HOXB2 is one of the topranked genes in the NPM1-mutated signature, there is no data regarding the hematopoietic effects of overexpression of this gene.
These observations suggest that this unique pattern of HOX gene dysregulation may be important in NPM1-mutationmediated leukemogenesis. However, the mechanisms by which NPM1 mutations result in aberrant HOX expression and leukemic transformation remain unclear. Dysregulation of HOX expression in MLL-rearranged leukemia may be explained by the action of MLL as a transcriptional regulator of HOX genes, but this is unlikely to be the case for NPM. It is unclear if NPM directly influences HOX expression via a different pathway, for example growth factor signaling pathways, or whether NPM1 mutations result in arrested development of hematopoietic precursors at a primitive stage with high HOX expression.
Recent studies have demonstrated that NPM is an abundant nucleolar protein that shuttles between nucleus and cytoplasm. NPM is likely to have a crucial role in normal cellular homeostasis, and subserves a number of cellular functions whose disruption may contribute to leukemogenesis in NPM1-mutated AML. 54 These include regulation and stabilization of tumor suppressors such as Arf and P53, maintenance of genomic integrity and stability, regulation of apoptosis and nucleosomal biosynthesis. NPM1 mutation are, thus, likely to perturb multiple cellular pathways in addition to HOX gene regulation. It is also likely that the biologic effects of NPM mutations are dependent on cellular context, and that NPM1 mutations alone do not induce leukemia. Thus defining the overall collection of mutation that work collaboratively with NPM1 mutations should provide valuable insights into the pathways that must be Figure 4 Quantitative RT-PCR analysis of (a) HOXB2 expression levels and (b) HOXB6 expression levels in NPM1-mutated and MLLrearranged AML. Expression of HOXB2 and HOXB6 is significantly higher in NPM1-mutant cases than MLL-rearranged MLL. t-test P-values are shown.
dysregulated to lead to transformation in this recently identified subtype of leukemia.
